Weisberg E, Fraser I S, Lacarra M, Mishell D R, Alvarez F, Brache V, Nash H A
Sydney Centre for Reproductive Health Research, Family Planning NSW, Australia.
Contraception. 1999 May;59(5):311-8. doi: 10.1016/s0010-7824(99)00035-9.
A combined contraceptive vaginal ring designed to last 12 months was tested at three clinic sites. This ring released approximately 1 mg of norethindrone acetate (NET-Ac) and 20 micrograms of ethinyl estradiol (EE) daily. A total of 60 women were enrolled to use the ring in a schedule of 3 weeks in/1 week out. Serum norethindrone (NET) and ethinyl estradiol (EE) levels were assayed twice weekly in cycles 6, 9, and 13. Mean NET concentrations between cycles 6 and 9 were relatively stable between 13 and 19 nmol/L but showed a 10%-21% decrease in all centers between cycles 9 and 13. Mean EE concentrations ranged from 75 to 103 pmol/L, but did not have the same decrease as NET between cycles 9 and 13. Cycles with progesterone peaks (> 9.6 nmol/L) compatible with some luteal activity occurred in 4% of cycles sampled in Sydney, 3% in Santo Domingo, and 26% in Los Angeles. Half of these cycles exhibited at least one progesterone value > 32 nmol/L with three of 18 occurring in noncompliant cycles. Heavier body weight was associated with increased probability of luteal activity. Based on serum estradiol peaks > 400 pmol/L, eight of 81 cycles appeared to have marked follicular activity with no luteal activity. No pregnancies occurred. Nausea was reported by about half the subjects in approximately 10% of the visits (mainly in the first 1-2 days in the first cycle immediately after ring insertion). Vomiting was reported by 20% of subjects early in the first cycle only. Headache was reported on occasion by nearly 50% of the women, but the relationship to ring use was uncertain. Vaginal discharge was reported by 17 women (82% of these were from one clinic). Of 60 women, 14 discontinued before completing the study, but only two discontinuations were for medical reasons. Small but statistically significant changes occurred in lipid levels in two of the three centers. All changes remained within normal limits and were similar to those seen with many oral contraceptives. It appears that this ring may perform slightly differently in different populations, but is a highly satisfactory method of contraception for many women. Minor modifications in design could provide higher levels of steroid release and in the later months of the ring life span would assure continuing high levels of contraceptive protection for heavier women.
一种设计可使用12个月的复方避孕阴道环在三个临床地点进行了测试。该阴道环每天释放约1毫克醋酸炔诺酮(NET-Ac)和20微克炔雌醇(EE)。共有60名女性按3周使用/1周停用的方案佩戴该阴道环。在第6、9和13个周期每周两次测定血清炔诺酮(NET)和炔雌醇(EE)水平。第6和9个周期之间的平均NET浓度在13至19纳摩尔/升之间相对稳定,但在所有中心第9和13个周期之间均下降了10%-21%。平均EE浓度在75至103皮摩尔/升之间,但在第9和13个周期之间没有与NET相同的下降。悉尼4%的采样周期、圣多明各3%的采样周期以及洛杉矶26%的采样周期出现了与一些黄体活性相符的孕酮峰值(>9.6纳摩尔/升)。这些周期中有一半至少出现一次孕酮值>32纳摩尔/升,18个周期中有3个出现在未依从周期。体重较重与黄体活性增加的可能性相关。根据血清雌二醇峰值>400皮摩尔/升,81个周期中有8个似乎有明显的卵泡活性但无黄体活性。未发生妊娠。约10%的就诊中约一半受试者报告有恶心(主要在首次插入阴道环后的第一个周期的前1-2天)。仅在第一个周期早期有20%的受试者报告有呕吐。近50%女性偶尔报告有头痛,但与使用阴道环的关系不确定。17名女性报告有阴道分泌物(其中82%来自一个诊所)。60名女性中有14名在完成研究前停药,但只有2例因医学原因停药。三个中心中有两个中心的血脂水平发生了微小但有统计学意义的变化。所有变化均在正常范围内,且与许多口服避孕药所见相似。看来该阴道环在不同人群中的表现可能略有不同,但对许多女性来说是一种非常令人满意的避孕方法。设计上的微小改进可提供更高水平的甾体释放,并且在阴道环使用寿命的后期几个月将确保体重较重的女性持续获得高水平的避孕保护。